MetaCap

Fortress Biotech (FBIO) vs Polaryx Therapeutics (PLYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Polaryx Therapeutics is the larger company by market cap ($66.3 million vs $64.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBIO-39.68%PLYX-96.20%
+25%-39%-102%
Feb 2, 20261 yearNov 20, 2026
FBIO-41.90%PLYX-85.07%
+15%-37%-90%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBIO versus PLYX key metrics
MetricFBIOPLYX
Share price$1.90$1.33
Market cap$64.11M$66.30M
1-day change+7.34%-11.92%
YTD return-48.09%—
1-year return-26.64%—
5-year return-95.52%—
P/E ratio (TTM)0.83—
EPS (TTM)$2.30$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.26M—
Revenue growth (YoY)+9.69%—
Net income (latest FY)$6.82M$-8.98M
Gross margin66.92%—
Operating margin-111.00%—
Net margin10.77%—
52-week high$4.53$48.91
52-week low$1.64$1.30
Distance from 52-week high-58.06%-97.28%
Analyst consensusnonenone
Avg. price target upside+163.16%+463.91%
Average volume281.49K36.42K
Shares outstanding33.74M49.85M
Employees782
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

FBIO vs PLYX FAQ

Which is bigger, Fortress Biotech or Polaryx Therapeutics?

Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $66.30M compared with $64.11M for Fortress Biotech (FBIO).

Are Fortress Biotech and Polaryx Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons